STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Sign Up to like & getrecommendations! Published in 2021 at "Human cell"
DOI: 10.1007/s13577-021-00582-4
Abstract: Gefitinib is known as epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) while an increasing number of patients with non-small cell lung cancer (NSCLC) are becoming resistant to EGFR-TKI. Therefore, innovative methods are urgently needed to… read more here.
Keywords: hcc827 cells; inhibitor; gefitinib; stat3 inhibitor ... See more keywords
Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway
Sign Up to like & getrecommendations! Published in 2017 at "Bioscience Reports"
DOI: 10.1042/bsr20160478
Abstract: Recent evidence supports a role for microRNA-223 (miR-223) in modulating tumor cell sensitivity to chemotherapeutic drugs; however, its role in cellular resistance to the effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) used… read more here.
Keywords: hcc827 cells; hcc827; erlotinib; expression ... See more keywords